Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts-Reference-Cited by-同舟云学术

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts

Published:2014-07 Issue: Volume:58 Page:13-19
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Conte Enrico,Gili Elisa,Fagone Evelina,Fruciano Mary,Iemmolo Maria,Vancheri Carlo

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference32 articles.

1. Pirfenidone treatment of idiopathic pulmonary fibrosis;Azuma;Ther. Adv. Respir. Dis.,2012

2. Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection1;Bizargity;Transplantation,2012

3. Pirfenidone inhibits transforming growth factor-beta1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-193;Choi;Mol. Vis.,2012

4. Quantitative evaluation of interleukin-12 p40 gene expression in peripheral blood mononuclear cells46;Conte;Immunol. Invest.,2008

5. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms;Conte;PLoS ONE,2011

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study;Pulmonary Pharmacology & Therapeutics;2024-03

2. Osteoprotegerin is an early marker of the fibrotic process and of antifibrotic treatment responses in ex vivo lung fibrosis;2024-02-02

3. Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases;Pharmacology & Therapeutics;2024-01

4. Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension;Pulmonary Circulation;2024-01

5. Differentiation of Uc-MSCs into insulin secreting islet-like clusters by trypsin through TGF-beta signaling pathway;Differentiation;2024-01